Skip to Main Content

BOSTON — Vertex Pharmaceuticals reshaped the way doctors treat cystic fibrosis, turning what was once a childhood death sentence into a manageable condition — and making the Boston biotech a multibillion-dollar company in the process.

Its next goal? Reproducing that success.


The company’s executives on Tuesday laid out an ambitious vision for the company’s future, one they dubbed “Vertex 3.0.” It’s one in which Vertex is taking aim at everything from diabetes to sickle cell disease to pain. Many of these programs have reached clinical trials, with others buttressed by laboratory studies supporting the safety and effectiveness of experimental therapies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.